/
DCF Valuation
Base-case fair value
$391.36
Intrinsic $521.81 · 25% MOS
Current price: $226.93
Base-case summary
Our base-case DCF for Jazz Pharmaceuticals plc (JAZZ) projects 10 years of free cash flow growth at 11.1% for years 1–5 and 5.6% for years 6–10, anchored to 11.1% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $1.3B in trailing free cash flow, this produces an intrinsic value of $521.81 per share. A 25% safety margin gives a fair value of $391.36, suggesting the stock is currently 72% undervalued against the $226.93 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$1.3B
Cash & equivalents
$1.8B
Total debt
$5.4B
Shares outstanding
66M